Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential Anticancer Effects of Limonene Associated with Reactive Oxygen Species Generation, Apoptosis Induction, and NF-κB Modulation in Papillary Renal Cell Carcinoma: A Preliminary Study.

Current developments in nutrition·2026
Same author

Congenital cytomegalovirus infection drives oligoclonal expansion of cytotoxic γδ T cells from early fetal progenitors.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

Arctigenin Suppresses Breast Cancer Growth In Vitro and In Vivo Through Subtype-Specific Multi-Targeting Activity.

International journal of molecular sciences·2026
Same author

Single-cell spatial transcriptomics of formalin-fixed, paraffin-embedded biopsies reveals colitis-associated cell networks.

The Journal of clinical investigation·2026
Same author

Metformin and Flutamide Combination Therapy's Efficacy and Safety in Prostate Cancer Cell Lines.

Prostate cancer·2026
Same author

Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancer.

Journal for immunotherapy of cancer·2026

Related Experiment Video

Updated: Jun 27, 2025

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.9K

EMP2 Serves as a Functional Biomarker for Chemotherapy-Resistant Triple-Negative Breast Cancer.

Ann M Chan1,2, Brian Aguirre1, Lucia Liu1

  • 1Department of Pathology Lab Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.

Cancers
|April 27, 2024
PubMed
Summary

Epithelial membrane protein 2 (EMP2) predicts poor outcomes in triple-negative breast cancer (TNBC) patients receiving chemotherapy. Targeting EMP2 with docetaxel reduced tumor burden, suggesting a new therapeutic strategy for TNBC.

Keywords:
biomarkerchemotherapyepithelial membrane protein 2triple-negative breast cancer

More Related Videos

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:29

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

110
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

Related Experiment Videos

Last Updated: Jun 27, 2025

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.9K
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:29

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

110
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

Area of Science:

  • Oncology
  • Molecular Biology

Background:

  • Triple-negative breast cancer (TNBC) presents aggressive behavior and poor survival rates.
  • Current chemotherapy for TNBC lacks specific targets, leading to suboptimal outcomes.

Purpose of the Study:

  • To investigate epithelial membrane protein 2 (EMP2) as a prognostic biomarker for TNBC chemotherapy response.
  • To evaluate the therapeutic potential of targeting EMP2 in TNBC models.

Main Methods:

  • Explored EMP2 expression at transcriptomic and protein levels in TNBC patients.
  • Assessed the correlation between EMP2 expression and patient survival after taxane-based chemotherapy.
  • Investigated the efficacy of combined EMP2 targeting and docetaxel treatment in TNBC models.

Main Results:

  • High EMP2 expression correlated with poor overall survival in TNBC patients treated with taxane-based chemotherapy.
  • Combined EMP2 targeting and docetaxel treatment significantly reduced tumor load in preclinical TNBC models.

Conclusions:

  • EMP2 serves as a prognostic biomarker for chemotherapy response in TNBC.
  • Targeting EMP2 offers a potential therapeutic strategy for chemotherapy-resistant TNBC.